Literature DB >> 8392505

Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer.

J G Armstrong1, C Burman, S Leibel, D Fontenla, G Kutcher, M Zelefsky, Z Fuks.   

Abstract

PURPOSE: The specific aim of 3-dimensional conformal radiation therapy is to improve the target dose distribution while concomitantly reducing normal tissue dose. Such an approach should permit dose escalation until the limits of acceptable normal tissue toxicity are reached. To evaluate the feasibility of tumor dose escalation for nine patients with lung cancer, we determined the dose distribution to the target and normal tissues with 3-dimensional conformal radiation therapy and conventional planning. METHODS AND MATERIALS: Plans were compared to assess adequacy of dose delivery to target volumes, dose-volume histograms for normal tissue, and normal tissue complication probabilities (NTCP) for nine patients with lung tumors.
RESULTS: The mean percentage of gross disease which received < or = 70.2 Gy with 3-dimensional conformal radiation therapy (3DCRT) was 40% of the mean percentage of gross disease which received < or = 70.2 Gy with conventional treatment planning (CTP). The mean NTCP for lung parenchyma with 3DCRT was 36% of the mean NTCP with CTP. The mean esophageal NTCP with 3DCRT was 88% of the mean NTCP with CTP.
CONCLUSION: This preliminary analysis suggests that three dimensional conformal radiation therapy may provide superior delivery of high dose radiation with reduced risk to normal tissue, suggesting that this approach may have the potential to improve the therapeutic ratio of high dose radiation therapy for lung cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8392505     DOI: 10.1016/0360-3016(93)90289-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?

Authors:  Millie Das; Mohamed H K Abdelmaksoud; Billy W Loo; Nishita Kothary
Journal:  Curr Treat Options Oncol       Date:  2010-06

2.  Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.

Authors:  John L Mikell; Theresa W Gillespie; William A Hall; Dana C Nickleach; Yuan Liu; Joseph Lipscomb; Suresh S Ramalingam; Raj S Rajpara; Seth D Force; Felix G Fernandez; Taofeek K Owonikoko; Rathi N Pillai; Fadlo R Khuri; Walter J Curran; Kristin A Higgins
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

Review 3.  Three-dimensional conformal radiotherapy for lung cancer: promises and pitfalls.

Authors:  Rakesh R Patel; Minesh Mehta
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

4.  Change in dose distribution of three-dimensional conformal radiotherapy during treatment for lung tumor.

Authors:  Kazunari Yamada; Keisuke Iwai; Ryu Kawamorita; Yoshishige Okuno; Toshifumi Nakajima
Journal:  Radiat Med       Date:  2006-02

5.  Conformal radiotherapy for lung cancer: interobservers' variability in the definition of gross tumor volume between radiologists and radiotherapists.

Authors:  Chiang J Tyng; Rubens Chojniak; Paula N V Pinto; Marcelle A Borba; Almir G V Bitencourt; Ricardo C Fogaroli; Douglas G Castro; Paulo E Novaes
Journal:  Radiat Oncol       Date:  2009-08-05       Impact factor: 3.481

6.  Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer.

Authors:  Ki Ho Seol; Jeong Eun Lee; Joon Yong Cho; Deok Heon Lee; Yangki Seok; Min Kyu Kang
Journal:  Thorac Cancer       Date:  2017-09-14       Impact factor: 3.500

7.  The risks and trends of cardiac-specific mortality associated with chemotherapy or radiotherapy in a large cohort of non-elderly patients with non-small cell lung cancer.

Authors:  Kai-Ting Jiang; Ding-Zhi Huang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.